Innocan Pharma's BI Sky Global Achieves HRIPT Testing Completion and Daily Sales Milestone Innocan Pharma's subsidiary BI Sky Global has completed crucial HRIPT testing and reached a remarkable sales target of 5,000 units daily in 2024.

Innocan Pharma's BI Sky Global Achieves HRIPT Testing Completion and Daily Sales Milestone #USA #Calgary #Innocan_Pharma #BI_Sky_Global #HRIPT_Testing